Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.36% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Jun 30, 2023
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-041468General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-345.43% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
-64.00% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
227.79% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
29.37% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-272.93% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
28.15% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
14.33% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.00%
- Current
- 0.36%
- Delta
- 0.36%
- Previous
- -229.69%
- Current
- -345.43%
- Delta
- -115.74%
- Previous
- -53.14%
- Current
- -64.00%
- Delta
- -10.86%
- Previous
- 171.70%
- Current
- 227.79%
- Delta
- 56.09%
- Previous
- 45.33%
- Current
- 29.37%
- Delta
- -15.95%
- Previous
- -268.26%
- Current
- -272.93%
- Delta
- -4.67%
- Previous
- 23.79%
- Current
- 28.15%
- Delta
- 4.36%
- Previous
- 14.05%
- Current
- 14.33%
- Delta
- 0.28%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA historical state 2023-09-30 →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA Fundamental State →Transitioned To · RKDA CAPEX_INTENSITY_INCREASED →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA GROWTH_DECREASED →Transitioned To · RKDA INVENTORY_PRESSURE_INCREASED →Transitioned To · RKDA MARGIN_DECREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.